The aim of this study was to determine the value of 18F-FDG uptake on screening PET/CT images for the prediction of Helicobacter pylori (H. pylori) infection and chronic atrophic gastritis. Among subjects who underwent 18F-FDG PET/CT for cancer screening from April 2005 to November 2015, PET/CT images were analyzed in 88 subjects who had gastrointestinal fiberscopy within 6 months. The volumes of interest (VOIs) were placed in the fornix, corpus and antrum of the stomach to determine maximal standardized uptake value (SUVmax) and mean SUV (SUVmean). Receiver operating characteristic curve (ROC) analysis was performed to determine the diagnostic performance of SUV indicators in predicting H. pylori infection and chronic atrophic gastritis. SUV indicators of the stomach were significantly higher in subjects with H. pylori infection than those without (from P < 0.001 to P < 0.05). ROC analysis revealed that SUVmean had the highest performance in predicting H. pylori infection (AUC 0.807) and chronic atrophic gastritis (AUC 0.784). SUVmean exhibited the sensitivity of 86.5 % and the specificity of 70.6 % in predicting H. pylori infection, and the sensitivity of 75.0 % and 78.6 % in predicting chronic atrophic gastritis. Assessment of 18F-FDG uptake in the stomach reflecting active inflammation is useful in predicting patients with H. pylori infection and subsequent chronic atrophic gastritis which is closely associated with the risk of gastric neoplasms.
We aimed to confirm the effect of combined treatment with celecoxib and rebamipide would be more effective than celecoxib alone for prevention of upper gastrointestinal (GI) events. Patients with rheumatoid arthritis, osteoarthritis, and low back pain were enrolled in this study. Patients were randomized to two groups: a monotherapy group (100 mg celecoxib twice daily) and a combination therapy group (add on100 mg of rebamipide three times a day). The GI mucosal injury was evaluated by endoscopic examination before treatment and at 3 months. The primary endpoint was to evaluate the preventive effect of the combination therapy group for GI events, endoscopic upper GI ulcers and intolerable GI symptoms, compared with the monotherapy group. Seventy-five patients were enrolled. Sixty-five patients were analyzed (16 males, 49 females; mean age: 67 ± 13 years). The prevalence of upper GI events, five of endoscopic GI ulcers and one of intolerable GI symptoms, were 6/34 (17.6 %) in the monotherapy group and 0/31 in the combination therapy group, p = 0.0252. The combination therapy group was more effective than the monotherapy group for prevention of upper GI events in this study. Rebamipide might be a candidate for an option to prevent COX-2 selective inhibitor-induced upper GI events.
Acute necrotizing esophagitis (ANE) is a severe form of acute esophagitis that appears dark black in color (”black esophagus”) at endoscopy due to mucosal necrosis [ 1 ]. ANE is an uncommon condition of unknown etiology. Grudell et al. reported that among 52 cases of ANE, seven cases involved massive gastroesophageal reflux [ 2 ]. As gastroesophageal reflux is one of the proposed causes of ANE [ 3 ] [ 4 ], treatment generally includes administration of a proton pump inhibitor (PPI). A 67-year-old man complained of vomiting and chest pain 5 days after surgery for a vitreous hemorrhage. The patient had a history of diabetes mellitus, hypertension, hyperlipidaemia, and angina pectoris. Endoscopy revealed a black-appearing esophageal mucosa extending from the proximal two thirds of the esophagus to the cardia ([ Fig. 1 ]). After 6 days of treatment that included oral nutritional rest for 1 week and rabeplazole (20 mg/day), the mucosal surface was diffusely covered with whitish exudates ([ Fig. 2 ]), and biopsy specimens consisted of necrotic debris. By continuing to take rabeplazole for 4 months after release from hospital, the patient was cured of esophagitis ([ Fig. 3 ]). However, 37 days after finishing the rabeplazole treatment, the patient returned due to recurring vomiting and chest pain. Endoscopy revealed a reoccurrence of the black-appearing esophageal mucosa and whitish exudates, as well as mucosal bleeding ([ Fig. 4 ]). Upon reestablishment of the treatment described previously, the relapsed ANE improved considerably within 3 weeks. With continued administration of rabeplazole, the ANE has not relapsed. Fig. 1 Endoscopy revealed a black-appearing esophageal mucosa extending from the proximal two thirds of the esophagus to the cardia. Fig. 2 After 6 days of treatment, the esophageal surface was diffusely covered with whitish exudates. Fig. 3 By continuing to take rabeplazole for 4 months after release from hospital, the patient was cured of esophagitis. Fig. 4 The patient returned 37 days after finishing the rabeplazole treatment, and endoscopy revealed a reoccurrence of the black-appearing esophageal mucosa and whitish exudates, as well as mucosal bleeding. To our knowledge, this is the first reported case of a relapse of ANE [ 2 ] [ 5 ]. In this case, relapse may have been associated with acid backflow, and we hypothesize that if the patient were to discontinue the PPI, he would experience another relapse. Endoscopy_UCTN_Code_CCL_1AB_2AC_3AD
A 65-year-old man with a history of cerebral infarction was referred to our hospital for investigations to find the cause of recurring melena, which he had been experiencing for 2 months. At a previous hospital, he had had an upper gastrointestinal endoscopy and a colonoscopy that failed to show a cause for his bleeding, and an abdominal computed tomography (CT) scan, which detected a strongly enhancing mass in the upper abdomen ([Fig. 1]). We carried out double-balloon endoscopy using the antegrade approach and found a pedunculated polyp in the jejunum, the surface of which was completely covered with a white coating ([Fig. 2]). The endoscope could not be inserted beyond this because the mass was occupying the lumen. Endoscopic biopsies revealed inflammatory cells with no evidence of malignancy. The polyp was considered to be the cause of his bleeding, and a segmental resection of the small intestine was performed. Examination of the resected specimen showed that the polyp was 33 mm in diameter ([Fig. 3]), and histology revealed that it was composed of numerous capillaries in an edematous stroma with an inflammatory infiltrate ([Fig. 4]). These findings were consistent with pyogenic granuloma. After surgery, there was no recurrence of melena over the subsequent 18 months. Pyogenic granulomas usually occur on the skin and in the oral cavity, and rarely in the gastrointestinal tract. Thirteen cases of pyogenic granuloma in the small intestine have been reported [1] [2] [3], and most of these were reported to have an irregular shape without surface ulceration and were reddish in color. Because pyogenic granulomas are hemorrhagic tumors, they are usually less than 20 mm in diameter (median 13 mm). To the best of our knowledge, only one case of a polyp larger than 30 mm has been reported [4], and our case is the largest pyogenic granuloma so far reported in the small intestine. Pyogenic granuloma should be considered as a rare cause of obscure gastrointestinal bleeding, although it is difficult to diagnose pyogenic granuloma prior to surgery because of its unusual endoscopic appearance. Endoscopy_UCTN_Code_CCL_1AC_2AC
7 February 2023 in Journal of Gastroenterology and Hepatology
Background: The role of Helicobacter pylori in the pathogenesis of reflux esophagitis is controversial. This study investigated the frequency of reflux esophagitis before and after H. pylori eradication in patients having endoscopic submucosal dissection for early gastric cancer. Methods: This study included 160 patients that fulfilled the study’s criteria. Endoscopy was performed before and after H. pylori eradication, and reflux esophagitis was evaluated during the follow-up period. Results: Seropositivity for H. pylori in patients with early gastric cancer was 68.8%, 101 of them received eradication therapy. During the follow-up period, the incidence of reflux esophagitis increased from 3.1% to 18.8% in the successful eradication group but no case of reflux esophagitis was observed in the failed eradication group. The univariate and multivariate analyses showed a significant correlation between successful H. pylori eradication rate and the development of reflux esophagitis. Conclusions: This study demonstrated that a successful H. pylori eradication therapy is a risk factor for newly developed reflux esophagitis in patients with endoscopic submucosal dissection for early gastric cancer.